US and European stock markets stalled or trimmed gains on Friday after a bullish week buoyed by US data and upbeat company earnings.

GSK was trying to revive a product pulled from US markets in 2022. Its shares fell 4.6 per cent, or 65p, to 1348p.

The FDA oncologic drugs advisory committee voted against the approval of GSK’s blood cancer treatment Blenrep, delivering a setback to the drugmaker’s efforts to reintroduce the drug to the U.S.

Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit/risk profile at the proposed dosage of GSK plc’s ...

Despite the setback with the Oncologic Drugs Advisory Committee vote, GSK emphasizes the unmet need in multiple myeloma and ...

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

Chief executive Kris Licht said the sale simplifies Reckitt’s business and allows it to concentrate on its portfolio of 11 “high-growth, high-margin” brands, such as Dettol, Gaviscon, Nurofen and ...

Administering Shingrix previously required combining a lyophilised antigen with a liquid adjuvant from two separate vials.

FDA advisers on Thursday voted against GSK's blood cancer drug Blenrep, finding that its risks outweighed its benefits at the ...

Reckitt Benckiser shares have lifted 2% or 110p to 5092p after the consumer goods giant secured a private equity buyer for ...